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Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75%
of prolactinomas patients treated for at least 2 years. In contrast, it is not well estab-
lished whether CAB therapy can be successfully withdrawn after a failed first attempt.This
prospective open trial was designed to address this topic and to try to identify possible
predictor factors. Among 180 patients with prolactinomas on CAB therapy, the authors
selected those who fulfilled very strict criteria, particularly additional CAB therapy for at
least 2 years, normalization of serum prolactin (PRL) levels following CAB restart, no tumor
remnant >10 mm, no previous pituitary radiotherapy or surgery; and current CAB dose
≤1.0 mg/week. Recurrence was defined as an increase of PRL levels above the upper
limit of normal. A total of 34 patients (70.6% female) treated with CAB for 24–30 months
were recruited. Ten patients (29.4%) remained without evidence of recurrence after 24–
26 months of follow-up. Twenty-four patients (70.6%) recurred within 15 months (75%
within 12 months) after drug withdrawal and ~80% were restarted CAB. Median time
to recurrence was 10.5 months (range, 3–15). Despite overlapping values, non-recurring
patients had significantly lower mean PRL levels before withdrawal. Moreover, the recur-
rence rate was lower in subjects without visible tumor on pituitary magnetic resonance
imaging (MRI) than in those with small remnant tumor (60 vs. 79%), though the difference
was not statistically significant (P=0.20). No other characteristic could be identified as
a predictor of successful CAB discontinuation. In conclusion, a second attempt of CAB
withdrawal after two additional years of therapy may be successful, particularly in patients
with lower PRL levels and no visible tumor on pituitary MRI. Close monitoring of PRL level
is mandatory, especially within the first year after withdrawal, where most recurrences are
detected.
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INTRODUCTION
Prolactinomas are the most common pituitary tumors and
account for about half of cases (1, 2). Their prevalence in the gen-
eral population ranges from 6 to 50 per 100,000 (3, 4). Without
appropriate treatment, prolactinomas may cause hypogonadism,
infertility, bone loss, headaches, and visual fields defects from
mass effect (5), as well as metabolic disorders (6). Based on their
size, prolactinomas are classified into macro adenoma (>1 cm) or
micro adenoma (<1 cm) (5). The mainstay of therapy involves the
use of dopamine agonists (DA), even for patients with optic chi-
asm compression by large tumors (7, 8). Cabergoline (CAB) has
been largely recommended as the first line agent, due to its bet-
ter tolerability and higher efficacy in normalizing prolactin (PRL)
levels and inducing tumor shrinkage, compared to bromocriptine
(2, 5, 7, 8).
Studies of patients treated with CAB for microprolactinomas
and macroprolactinomas have reported normalization of PRL
levels in 75–90%, associated with an average decrease in tumor
volume of 72–92% (9–11). In the Brazilian multicenter study on
hyperprolactinemia, CAB therapy was able to induce significant
tumor shrinkage and complete disappearance of tumor in 80 and
57.5% of patients, respectively (7).
A major drawback of DA therapy is the potential need to keep
the medication indefinitely in many patients (2, 5). Indeed, despite
the widespread use of DA for patients with prolactinomas and
symptomatic idiopathic hyperprolactinemia for many decades, the
optimal treatment strategy and duration of treatment is still not
evident (12).
The 2011 Endocrine Society Clinical Practice Guideline rec-
ommends that, with careful clinical and biochemical follow-up,
therapy may be tapered and perhaps discontinued in patients
who have been treated with DA for at least 2 years, provided
they no longer have elevated PRL levels, nor detectable tumor
remnant on magnetic resonance imaging (MRI) (13). Accord-
ingly, four recent studies (n= 292) have demonstrated that CAB
therapy can be successfully discontinued, although hyperpro-
lactinemia recurrence rates ranged from 25 to 69% (mean, 49%)
(14–17).
On the other hand, it is not well established whether CAB ther-
apy can be successfully withdrawn after a failed first attempt (18).
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This prospective study was conducted to address this topic and to
try to identify possible predictor factors.
SUBJECTS AND METHODS
PATIENTS AND STUDY PROTOCOL
Among 180 patients with prolactinomas on CAB therapy rou-
tinely followed in the Division of Endocrinology, Hospital das
Clínicas, Federal University of Pernambuco, Recife, Brazil, the
authors selected those who fulfilled all of the following cri-
teria: (1) recurrence of hyperprolactinemia after a first CAB
withdrawal; (2) additional CAB therapy for at least 2 years; (3)
normalization of serum PRL levels following CAB restart; (4)
no tumor remnant ≥10 mm in its largest diameter on a recent
(<6 months) MRI; (5) no previous pituitary radiotherapy or
surgery; (6) no history of pregnancy over the past 3 years; (7)
negative screening for macroprolactinemia; and (8) current CAB
dose ≤1.0 mg/week.
After CAB withdrawal, the patients underwent clinical and hor-
monal (PRL levels) evaluation at 30 days and then every 3 months
thereafter. Those patients who experienced disease recurrence,
defined as an increase of PRL levels above the upper limit of nor-
mal (ULN) for gender, were removed from the study and restarted
CAB at the same previous dose, according to the severity of their
symptoms. They were also submitted to a pituitary MRI, aiming
to detect any change in tumor remnant volume.
The study protocol was approved by our Local Ethics and
Scientific Committees and all patients gave written informed
consent.
HORMONE ASSAYS AND IMAGING STUDIES
Serum PRL was measured using a two-site chemiluminescent
immunometric assay. The interassay coefficient of variation was
<5%. Normal range was 1.2–29.9 ng/ml (25–634µUI/ml) for
women and 2.6–18.1 ng/ml (55–384µUI/ml) for men.
The radiological study included the evaluation of the sellar
region by MRI with axial, coronal, and sagittal slices in T1, pre-
and post-gadolinium, and in T2. The MRI was evaluated by a
skilled neuroradiologist.
STATISTICAL ANALYSIS
For comparison of categorical variables, the chi-squared test or
the Fisher exact test were used where appropriate. A paired Stu-
dent’s t -test was performed for the comparative analysis of quan-
titative variables. Results are expressed as percentages or mean
values± SD, unless otherwise stated. A stratified analysis was per-
formed aiming at finding potential associations among clinical,
imaging, and biochemical characteristics with outcome. Values of
P< 0.05 were considered statistically significant. STATA version
10.0 and SPSS version 16.0 were used as statistical software.
RESULTS
CHARACTERISTICS OF PATIENTS
A total of 34 patients, 24 women and 10 men, fulfilled the selec-
tion criteria. Their individual baseline characteristics are shown
in Table 1. At diagnosis, their mean age was 32.7± 4.53 years
(range, 24(42; median, 32) and 11 (32.3%) had microade-
nomas. At withdrawal, their mean age was 41.35± 4.84 years
Table 1 | Patients characteristics prior to the introduction of
cabergoline therapy.
Patient Gender Age (years) PRL (ng/ml)a Tumor largest
diameter (cm)
1b F 24 180 1.5
2b F 34 660 2.8
3b M 38 880 3.2
4b F 26 312 0.8
5b M 38 280 2.2
6b M 30 94.7 0.9
7b F 33 146 0.8
8b F 30 172 0.8
9b F 36 460 2.2
10b F 26 214 1.8
11 F 28 420 2.2
12 M 38 140.5 0.9
13 F 36 255 1.2
14 M 36 124 1.2
15 M 32 334 1.5
16 F 31 720 2.1
17 F 38 95.2 0.8
18 M 35 177 0.8
19 M 37 335 1.6
20 M 37 240 1.2
21 F 34 212 0.9
22 M 36 910 3.5
23 F 34 163 0.9
24 F 38 382.4 1.6
25 F 36 412.5 1.8
26 F 35 265 0.9
27 F 37 511 2.1
28 F 24 223.4 1.3
29 F 30 242.7 1.2
30 F 27 712 2.5
31 F 35 180 0.8
32 F 30 310 1.7
33 F 33 256.3 1.3
34 F 40 314.4 1.4
M, male; F, female; PRL, prolactin.
aMultiply by 21.2 to convert to micro international units per milliliter.
bNon-recurring patients after cabergoline withdrawal.
(range, 31(52; median, 42) and they have been treated with CAB
for 27.03± 2.02 months (range, 24(30; median, 27). The aver-
age weekly CAB dose at second withdrawal was 0.89± 0.20 mg
(median, 1.0; range, 0.5(1.0) (Table 2).
Among the 146 patients not enrolled in the study, many
presented with at least two exclusion criteria. The most preva-
lent were weekly CAB dosage >1 mg (60%), treatment duration
<2 years (43%), tumor remnant >1 cm (16%), and concomitant
macroprolactinemia (10%).
RESPONSIVENESS TO CABERGOLINE WITHDRAWAL
The median follow-up time was 12 months (ranging from 3 to
26 months). Overall, 24 out of 34 patients (70.6%) recurred
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Table 2 | Patients characteristics at cabergoline (CAB) therapy withdrawal.
Patient Age (years) PRL (ng/ml)a Tumor remnant largest
diameter (cm)
CAB dose
(mg/week)
Duration of CAB
therapy (months)
Time for recurrence after
first withdrawal (months)
1b 32 9.6 NVT 0.5 24 9
2b 44 18.3 NVT 1 25 15
3b 52 15.8 0.5 1 30 6
4b 38 13.5 NVT 1 28 8
5b 42 15.3 NVT 1 28 9
6b 38 8.2 0.4 0.5 27 6
7b 40 12.5 NVT 0.5 29 12
8b 43 20.8 NVT 1 26 15
9b 39 22.5 0.5 1 30 9
10b 33 20.8 0.4 1 24 12
11 36 23.2 0.6 1 25 6
12 47 9.6 0.4 0.5 30 9
13 43 22.5 NVT 1 28 6
14 43 14.8 NVT 1 28 6
15 40 16.8 0.6 1 30 6
16 39 22.4 NVT 1 29 6
17 48 15.7 NVT 0.5 26 9
18 43 16 NVT 0.5 27 6
19 45 17.5 0.5 1 30 6
20 45 17.1 NVT 1 24 15
21 42 23.4 0.4 1 25 9
22 46 17.7 0.9 1 28 6
23 42 22.7 NVT 0.5 28 9
24 47 20.4 0.6 1 26 3
25 42 22.3 0.5 1 27 15
26 43 21.4 0.4 1 29 9
27 45 18.2 0.5 1 26 9
28 31 19.2 NVT 1 30 6
29 37 22.3 0.4 1 26 6
30 34 24.6 0.5 1 26 6
31 42 18.2 NVT 1 26 9
32 37 25.2 0.5 1 25 6
33 40 22.2 0.4 1 24 15
34 48 21.8 0.5 1 25 9
NVT, no visible tumor; PRL, prolactin.
aMultiply by 21.2 to convert to micro international units per milliliter.
bNon-recurring patients after cabergoline withdrawal.
within 15 months after CAB discontinuation (Figures 1 and 2).
Eighteen patients (75%) did so within 12 months, 11 (45.8%)
within 9 months, 7 (29.2%) within 6 months, and 2 (8.3%) within
3 months, respectively. Six patients (25%) relapsed after 12 months
of follow-up (Figures 1 and 2). Median time to recurrence was
10.5 months. The follow-up for patients who recurred was consid-
ered complete at the time of recurrence. Noteworthy, none of the
patients reached PRL levels above those found before CAB ther-
apy introduction. Thus,mean PRL levels were significantly lower at
the end of the follow-up (132.52± 48.3 vs. 366.88± 234.14 ng/ml,
P < 0.01).
Among recurring female patients, four presented with amen-
orrhea, eight with amenorrhea and galactorrhea, whereas five
remained asymptomatic. Concerning recurring male patients,
all developed hypogonadism-related symptoms. None of the
tumors enlarged in the patients experiencing recurrence. CAB was
restarted in all symptomatic recurring patients.
A total of 10 patients (29.4%) remained without clinical and
biochemical evidence of hyperprolactinemia recurrence after a
median follow-up time of 24 months (range, 24–26 months).
However, as shown in Figure 2, some increase in PRL levels was
observed in all these patients, though they remained in the normal
range.
PREDICTORS OF RESPONSIVENESS TO CABERGOLINE WITHDRAWAL
When recurring and non-recurring patients were compared, no
significant difference was found concerning age, gender, CAB
dose, and duration of CAB therapy before the second withdrawal
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FIGURE 1 | Characteristics and behavior of the patients with prolactinomas (PRLomas) who were evaluated.
FIGURE 2 | Comparison of PRL levels in non-recurring and recurring patients at withdrawal and at the end of the study. Recurrence was defined as PRL
values above the upper limit of normal.
(Table 3). Moreover, the proportion of patients with micro-
(29.2 vs. 40%) and macroadenomas (70.8 vs. 60%) was simi-
lar in both groups (P = 0.40) (Table 3), and so was their initial
tumor size (1.47± 0.65 vs. 1.7± 0.89 cm, P = 0.45) (Table 4).
Likewise, the mean time of recurrence after first CAB withdrawal
did not significantly differ (10.1± 3.28 vs. 8.0± 3.14 months;
P = 0.66).
By contrast, non-recurring patients had significantly lower
mean PRL levels (15.73± 4.87 vs. 19.8± 3.70 ng/ml, respectively,
P< 0.01) before second withdrawal (Table 3). Nevertheless, there
was a high degree of overlap in PRL values in both groups (Table 3).
Moreover, the recurrence rate was lower in subjects without visible
tumor on pituitary MRI than in those with small remnant tumor
(60 vs. 79%), though the difference was not statistically significant
(P = 0.20).
Noteworthy, demographic, biochemical, and imaging features
at the prolactinoma diagnosis did not significantly differ when
patients who recurred and the ones who remained in remission
were compared (Table 4).
DISCUSSION
The optimal duration of therapy with DA for patients with
prolactinomas or non-tumoral hyperprolactinemia remains con-
troversial (12). There is however strong and growing evidence
that discontinuation of dopamine agonist treatment may be suc-
cessfully achieved in a selected group of patients treated for at
least 2 years (14–17, 19, 20). A recent systematic review and
meta-analysis has shown that the pooled proportion of patients
with persisting normoprolactinemia after CAB withdrawal was
35% in a random effects model (21). In the series by Karlip
et al. (15), which involved 46 patients, the overall recurrence was
54% and the median time to recurrence was 3 months (range,
1(18 months) (15).
In contrast, it is currently unknown how valid and how use-
ful could be a second try to discontinue CAB administration in
patients whose first withdrawal did not succeed. Presently, there
are only data from a recent pilot prospective two-center study that
evaluated 17 patients who had undertaken a second course of CAB
treatment for at least 24 additional months (18). During a median
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Table 3 | Clinical, biochemical, and imaging characteristics in recurring
and non-recurring patients at withdrawal.
Recurring
patients
(n=24)
Non-recurring
patients
(n=10)
P -value
Age (years)
Range 31–48 32–52 0.64a
Mean±SD 41.87±4.55 40.10±5.72
Median 42.5 39.5
Female gender 17/24 (70.8%) 7/10 (70.0%) 0.63b
Male gender 7/24 (29.2%) 3/10 (30.0%) 0.63b
PRL (ng/ml)c
Range 9.6–25.2 8.2–22.5 0.01a
Mean±SD 19.8±3.70 15.73±4.87
Median 20.9 15.55
CAB dose before withdrawal
(mg/week)
Range 0.5–1.0 0.5–1.0 0.41a
Mean±SD 0.91±0.19 0.85±0.24
Median 1 1
CAB therapy duration before
withdrawal (months)
Range 24–30 24–30 0.85a
Mean±SD 27±1.96 27.1±2.28
Median 26.5 27.5
Pituitary mri findings
No visible tumor 9 (37.5%) 6 (60.0%) 0.20b
Tumor remnant
<1 cm
15 (62.5%) 4 (40.0%)
CAB, cabergoline; PRL, prolactin; MRI, magnetic resonance imaging.
aStudent’s t-test.
bFisher’s exact test.
cMultiply by 21.2 to convert to micro international units per milliliter.
follow-up of 6.1 months (ranging from 1 to 60 months) after CAB
withdrawal, 11 patients (64.7%) recurred. The estimated overall
recurrence rate was 44 events per 100 person-years. Moreover, the
estimated cumulative hazard of recurrence was 40% at 6 months
and 82% at 12 months (18).
We conducted a prospective trial to evaluate the outcome of a
second attempt of CAB withdrawal in 34 patients who met strict
selection criteria and have been treated with CAB for 24(30 months
(median, 27 months). All patients presented with normal PRL lev-
els, were given CAB doses (1 mg weekly, and had either no visible
tumors or small tumor remnants (<1 cm) on MRI. We found that
10 patients (29.4%) were able to maintain normal PRL levels for
up to 26 months following CAB withdrawal.
Concerning the 24 recurring subjects, all recurred within
15 months after CAB withdrawal, whereas 18 (75%) did so within
12 months. The median time to recurrence was 10.5 months.
Similarly, in the study by Kwancharoen et al. (18), most of the
recurrence (59%) also occurred within 1 year, whereas the median
time to recurrence was 6 months. Likewise, Karlip et al. (15) had
Table 4 | Clinical, biochemical, and imaging characteristics in recurring
and non-recurring patients at diagnosis.
Recurring
patients
(n=24)
Non-recurring
patients
(n=10)
P -value
Age (years)
Range 24–40 24–38 0.34a
Mean±SD 34.04±3.96 31.50±5.10
Median 35 31.5
Female gender 17/24 (70.8%) 7/10 (70.0%) 0.63b
Male gender 7/24 (29.2%) 3/10 (30.0%) 0.63b
PRL (ng/ml)c
Range 95.2–910 94.7–880 0.10a
Mean±SD 330.64±203.13 339.87±253.92
Median 260.65 247
MRI findings
Microadenomas 7 (29.2%) 4 (40%) 0.4b
Macroadenomas 17 (70.8%) 6 (60%)
CAB, cabergoline; PRL, prolactin; MRI, magnetic resonance imaging.
aStudent’s t-test.
bFisher’s exact test.
cMultiply by 21.2 to convert to micro international units per milliliter.
previously reported that 91% of the recurrences after the first
withdrawal were observed within the first year of discontinuation.
Thus, close clinical monitoring, especially within the first year
after withdrawal, should be carried out in all patients in whom
CAB therapy is discontinued.
According to previous studies, predictor factors for higher
chance of successful CAB withdrawn include lower PRL
levels, longer duration of treatment, tumor size (micro-
>macroadenomas), previous pituitary radiotherapy or surgery,
and pregnancy (5, 12, 13, 15, 16, 22). It has been shown that
women with prolactinomas who became pregnant have a higher
rate of remission than women without previous pregnancy (22,
23). Moreover, PRL levels are lower after delivery as compared
to levels before conception and complete remission of hyperpro-
lactinemia has been reported in 17–37% of women after pregnancy
(23). For that reason, we did not include in our study women with
history of pregnancy over the last 3 years.
Among our patients, a stratified analysis on clinical, pitu-
itary imaging, and biochemical characteristics, at the beginning
of the study and at CAB withdrawal, was unable to detect
parameters that could quite accurately identify individuals most
likely to respond to treatment discontinuation. However, non-
recurring patients had significantly lower mean PRL levels at
withdrawal. Furthermore, the recurrence rate was lower in patients
without visible tumor remnant on pituitary MRI than in sub-
jects with small tumor remnants (60 vs. 79%), though the dif-
ference was not statistically significant (P = 0.20). Accordingly,
Hu et al. (21) reported that patients who received the lowest
CAB dose and presented a significant reduction in tumor size
before withdrawal were more likely to achieve the best success
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Table 5 | Data from two studies specifically designed to evaluate the likelihood of successful second cabergoline (CAB) withdrawal after a failed
first attempt in well-controlled patients with prolactinomas.
Authors Number of
patients
evaluated
Definition of
recurrence
Number of
non-recurring
patients after
withdrawal
Number of
recurring
patients after
withdrawal
Median time
to recurrence
Recurrence rate
within 1 year
after CAB
discontinuation (%)
Duration of
treatment
Duration of
follow-up
after
withdrawal
Kwancharoen
et al. (19)
17 PRL level>ULN
for gender and age
6 (35.3%) 11 (64.7%) 6 months 59 24–93 months
(median, 48)
1–60 months
(median, 6.1)
Current study 34 PRL level>ULN
for gender
10 (29.4%) 24 (70.6%) 10.5 months 75 24–30 months
(median, 27)
3–26 months
(median, 12)
All 51 – 16 (31.4%) 35 (68.6%) – 68.6 – –
(P < 0.001). Likewise, in the series by Karlip et al. (15), size
of tumor remnant prior to withdrawal predicted recurrence
(18% increase in risk for each millimeter). By contrast, Kwan-
charoen et al. (18) could not depict any statistically significant
clinical predictors of recurrence, but this may have been influ-
enced by the small number of subjects enrolled in their trial
(n= 17).
It was previously reported that a nadir PRL at the time of first
withdrawal below 5.4 ng/ml was associated with a lower risk of
recurrence (16). In our series, although mean PRL levels before
withdrawal were lower in non-recurring subjects, individual PRL
values in both groups greatly overlapped (8.2–22.5 vs. 9.6–25.2),
as shown in Table 3.
Our study has some limitations. Notably, because of the small
number of patients, some or most clinical predictors may not have
reached statistically significance. It is also possible that some of
the patients presently on remission may recur later on. However,
recurrences beyond 2 years after CAB withdrawal have only seldom
been reported (15–17, 24). In the largest series to date (n= 200),
63 patients (31.5%) had recurrent hyperprolactinemia, 56% dur-
ing the first year, 33% during the second year, 11% during the third
year, and none thereafter (P< 0.001) (16, 24).
As shown in Table 5, a combined analysis of our findings and
those from the study by Kwancharoen et al. (18) would indicate
that about 31% of a selected group of patients with prolactinomas
treated with CAB for at least additional 24 months could benefit
from a second drug discontinuation. In four recent previous stud-
ies, which involved 292 patients with micro- or macroprolactin-
omas, the mean recurrence rate after first CAB withdrawal was
49% [range, 25–69% (14–16)]. Therefore, the chance of achieving
a successful second withdrawal seems to be similar to the first one.
However, further studies with a greater number of patients and
longer-term follow-up are clearly warranted.
A likely explanation for the successful second withdrawal could
be a longer exposure to CAB therapy and consequently to its
antiproliferative and pro-apoptotic effects on pituitary tumor cells,
described in several studies (25).
An additional advantage of CAB withdrawal would be to reduce
the risk of fibrotic cardiac valvulopathy, which has been associ-
ated with the use of DA therapy (26–28), particularly with the
higher dosage given to Parkinson’s disease patients (29, 30). How-
ever, most studies have not shown an increased prevalence of
significant cardiac valve regurgitation in patients with pituitary
diseases receiving CAB (13, 31–33).
In conclusion, the findings of the current study yield increasing
awareness that a second trial of CAB discontinuation should be
attempted in well-selected patients with prolactinomas who dis-
play normal PRL levels and tumor remnant <1 cm at low doses
(≤1 mg/week). Although our patients have been treated for two
or more years, the optimal length of therapy before attempting a
second CAB withdrawal still needs to be established. Patients with
lower PRL levels and no visible tumor on MRI seemed to be the
most likely to benefit from this approach but it was also effective
in subjects with small tumor remnants. It is essential however to
closely follow-up these patients and reinstitute therapy promptly
in symptomatic recurrent ones.
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